NDC 69097-908 – Lanreotide Acetate
Lanreotide Acetate 90 mg/.3mL · Injection · Subcutaneous
Product NDC69097-908
Product details
- Brand name
- Lanreotide Acetate
- Generic name
- Lanreotide Acetate
- Labeler
- Cipla USA Inc.
- Dosage form
- Injection
- Route
- Subcutaneous
- Marketing category
- ANDA · ANDA217193
- Marketed since
- May 30, 2025
- Listing expires
- December 31, 2026
- Pharmacologic class
- Somatostatin Analog
Active ingredients
- Lanreotide Acetate 90 mg/.3mL
Uses, dosage, side effects and warnings for Lanreotide Acetate →
Package NDC codes (1)
| Package NDC | Description | Since |
|---|---|---|
| 69097-908-67 | 1 POUCH in 1 CARTON (69097-908-67) / 1 SYRINGE in 1 POUCH / .3 mL in 1 SYRINGE | May 30, 2025 |
Recalls mentioning this NDC
- D-0423-2026 Apr 15, 2026 · Class II
Lack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
Other Lanreotide Acetate products
- 70121-2517 Lanreotide Acetate 120 mg/.5mL · Injection · Amneal Pharmaceuticals LLC
- 69097-870 Lanreotide Acetate 120 mg/.5mL · Injection · Cipla USA Inc.
- 69097-880 Lanreotide Acetate 60 mg/.2mL · Injection · Cipla USA Inc.
- 69097-890 Lanreotide Acetate 90 mg/.3mL · Injection · Cipla USA Inc.
- 69097-906 Lanreotide Acetate 120 mg/.5mL · Injection · Cipla USA Inc.
- 69097-907 Lanreotide Acetate 60 mg/.2mL · Injection · Cipla USA Inc.
- 76282-718 Lanreotide Acetate 60 mg/.2mL · Injection · EXELAN PHARMACEUTICALS, INC.
- 76282-719 Lanreotide Acetate 90 mg/.3mL · Injection · EXELAN PHARMACEUTICALS, INC.
- 76282-720 Lanreotide Acetate 120 mg/.5mL · Injection · EXELAN PHARMACEUTICALS, INC.